DNA2.0, Inc. (www.DNA20.com), a leader in synthetic biology, today announced the introduction of RNAissanceTM genes. These twenty thousand RNAi-resistant human genes are immediately available at the company’s comprehensive online gene catalog, PlanetGeneTM, which already offers twenty-five thousand expression-optimized human genes for scientific research. RNAissance genes provide a simple and rapid way to ensure that the correct gene target is identified using RNAi. This can prevent wasting months of experimentation and hundreds of thousands of dollars studying spurious targets. RNAissance is one of many synthetic gene product lines that DNA2.0 will offer on PlanetGene. The expansion of PlanetGene continues the company’s commitment to close the gap between information and experimentation. DNA2.0 provides cost-effective and innovative tools for research to accelerate drug discovery and product development.
“RNAi has quickly become the method of choice to identify gene function in mammalian cells,” said Jeremy Minshull, president of DNA2.0. “However, several recent reports show that many non-specific effects can be induced by siRNA. We have addressed this problem by developing RNAissance genes, and we are excited to add RNAissance to the PlanetGene catalog, offering researchers a new, low-cost synthetic gene which is both a perfect control, and a potential starting point for a new set of experiments.”
About DNA2.0, Inc.
DNA2.0 is the developer of two platform technologies, the DNA-2-GoTM gene synthesis process and DeNovo GenesTM, a protein engineering and sequence optimization technology. The firm’s charter is to exploit the synergy between a highly efficient gene synthesis process and new protein optimization technologies. DNA2.0 is applying its DNA-2-Go custom genes synthesis process and its DeNovo Genes platform technology to design and produce information-rich gene variants. These gene variants are synthesized individually and then tested for functional
activity. The data is analyzed and mapped as a mega dimensional projection of the correlated.
Contact Information:
DNA2.0, Inc.
Claes Gustafsson
corpcom@DNA20.com
(650) 853-8347